Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer

Published:2024-04 Issue: Volume:201 Page:113920
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Tarantino Paolo,Ajari Ogheneochuko^ORCID,Graham Noah,Vincuilla Julie,Parker Tonia,Hughes Melissa E.,Tayob Nabihah,Garrido-Castro Ana C.,Morganti Stefania,King Tari A.,Mittendorf Elizabeth A.,Curigliano Giuseppe^ORCID,Lin Nancy U.,Tolaney Sara M.

Publisher

Elsevier BV

Reference42 articles.

1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. c-erbB-2 oncoprotein expression in primary and advanced breast cancer;Lovekin;Br J Cancer,1991

4. Humanization of an anti-p185HER2 antibody for human cancer therapy;Carter;Proc Natl Acad Sci USA,1992

5. Trastuzumab--mechanism of action and use in clinical practice;Hudis;N Engl J Med,2007

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression;British Journal of Cancer;2024-06-28

2. The use of platelets as a clinical tool in oncology: opportunities and challenges;Cancer Letters;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP